It is with great pride that I share that the FDA has approved Amgen’s DLL3-targeting immunotherapy in advanced small cell lung cancer (SCLC). This is a pivotal milestone for patients. It’s also a full-circle moment for me and takes me back to my days working with Amgen’s Genome Analysis Unit. Back in 2010, we were on the hunt for tumor-specific antigens, or genes that are expressed in tumors and not in healthy tissue. We received SCLC tumor samples and observed consistent DLL3 overexpression. At that time, we recognized the potential of DLL3 as a therapeutic target. Today that potential was realized, and our discovery in the lab helped usher in a new treatment option for patients. Congratulations to everyone who helped make this advancement possible! #MyCompany
Today, the U.S. FDA approved Amgen’s delta-like ligand 3-targeting Bispecific T-cell Engager (BiTE®) immunotherapy in adults with extensive-stage small cell lung cancer (ES-SCLC). Amgen is proud to deliver the first targeted immunotherapy to this patient population. 🔗 Press release: https://amgen.ly/3X35AWL
Good news for SCLS patients! Congratulations! We do have EGFRviii specific antibody and EGFRviii x CD3 Tcell engager works. But we'd like to explore your evolved BiTE version if you are open for this! We also have positive data from EGFRviii-CAR-T, too.
Innovation, dedication and hard work bring hope to patients suffering from SCLC. Congrats to my friends in the Amgen Oncology TA ! Never stop
Congratulations! Its great news for patients and clear evidence that TCEs can be efficacious not only in heme malignancies but also solid tumors.
Congratulations a fantastic accomplishment, especially for patients that need therapeutic options in this disease.
And that is why we do what we do. Really inspiring work and much needed new therapy for patients- kudos
Congratulations to the BiTE discovery platform on this milestone from bench to bedside! 🙌🏼
Long time coming. Very well deserved. Congratulations to the whole host of people necessary to take this from start to finish.
Great to see such pioneering approaches being taken forward. Congrats to all involved in the herculean effort to get where you are now! 👌🥂
Kudos to Angela and her dedicated BiTE team at Amgen for bringing this breakthrough medicine to patients with this deadly disease 👏🏽
Vice President Global Program Head, Translational and Clinical Oncology at Regeneron
3moHaving started the DLL program nearly 5 years ago, it is so exciting to finally see our plans come to reality and patinetns fineally having a therapist for this terrible disease.